This trial will treat patients with platinum resistant ovarian, fallopian tube or primary peritoneal cancer as defined by a progression free interval within six months of completion of most recent platinum-based treatment with a combination of vismodegib and atezolizumab. Despite recent improvements in treatment of ovarian cancer with the introduction of PARP inhibitors, response rates to therapy in the platinum resistant setting remain dismal with response rates of only 10-20% reported for single agent cytotoxic therapies. Given the poor prognosis and limited treatment options for these patients, this population is considered appropriate for trials of novel therapeutic candidates.
Signed Informed Consent Form
Ability to comply with the study protocol, in the investigator's judgment
Histologically or cytologically confirmed epithelial ovarian, fallopian tube or primary peritoneal cancer
Platinum status, defined by disease progression during or following treatment with platinum-based chemotherapy within 6 months of completing therapy
Inability or unwillingness to swallow capsules
Inability or unwillingness to comply with study procedures
History of leptomeningeal disease
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
Ronald Buckanovich
Lead sponsor
University of Pittsburgh
Sponsor institution
Genentech, Inc.
Collaborator